ClinicalTrials.Veeva

Menu

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

P

Polish Lymphoma Research Group

Status and phase

Terminated
Phase 4

Conditions

Mycosis Fungoides
Lymphoma, T-Cell, Cutaneous

Treatments

Drug: Methotrexate
Drug: Interferon Alfa-2b

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT02323659
PLRG-14

Details and patient eligibility

About

Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.

Full description

Methotrexate and interferon are widely used drugs in treatment in patients with cutaneous T-cell Lymphomas. Efficacy and safety of both drugs have never been compared directly in one study.

Patients will be randomly assigned to receive Methotrexate or Interferon Alfa 2b. Treatment will continue until disease progression or the development of intolerable toxicities. Study is conducted to analyse and compare efficacy, safety and quality of life provided by Methotrexate or Interferon Alfa 2b.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Histologically confirmed primary cutaneous T-cell lymphoma (CTCL)
  2. Age ≥ 18 years
  3. Performance status WHO<=2
  4. Subject must have adequate bone marrow, renal and hepatic function
  5. Topical and phototherapy treatment failure in the past
  6. Signed informed consent

Exclusion criteria

  1. Subject has received prior systemic methotrexate or interferon therapy

  2. Unacceptable methotrexate or interferon treatment toxicity in the past

  3. Inadequate bone marrow, renal or hepatic function as follows:

    • Bone Marrow: Absolute neutrophil count (ANC) < 1,500/mm 3 (1.5 × 10 9 /L); Platelets <100,000/mm 3 (100 × 10 9 /L); Hemoglobin < 9.0 g/dL (1.4 mmol/L);
    • Renal function: Creatinine >1.5 x Upper limit of normal (ULN)
    • Hepatic function: Aspartate and Alanine transaminase (AST and ALT) >3× ULN; bilirubin > 1.5 × ULN
    • Active hepatitis B or hepatitis C
  4. anorexia

  5. major depression with suicidal ideation or suicide attempt in the past

  6. Symptomatic congestive heart failure

  7. Epilepsia or other symptomatic central nervous system dysfunction

  8. active skin infection not related to underlying CTCL, active Tuberculosis, HIV infection

  9. Subject is pregnant or lactating

  10. Psychiatric illness/social situation that would limit compliance with study requirements

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

Methotrexate arm
Active Comparator group
Description:
Patients assigned to receive methotrexate
Treatment:
Drug: Methotrexate
Interferon Alfa-2b
Active Comparator group
Description:
Patients assigned to receive Interferon alfa 2b
Treatment:
Drug: Interferon Alfa-2b

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems